Neurizon Therapeutics Limited has released a press release.
PharmAust Receives R&D Tax Incentive Refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- 93% take up in Options Offer
- PharmAust Raises $3.5 Million at a Premium
- PAA completes Phase 1 and files for Orphan Drug Designation
- Prospectus & Target Market Determination
- Appendix 4C and Quarterly Update
Later from Neurizon Therapeutics
- FightMND Invites PharmAust to Apply for Phase 2/3 Funding
- FDA Grants PharmAust Pre-IND Meeting
- PharmAust Partners with Berry Consultants for MND Phase 2/3
- FDA Provides Clear Feedback for ODD Approval
- Ethics Committee Approval for Open-Label MND Extension Study
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics